Management of transplant-eligible patients with newly diagnosed multiple myeloma

Jacob Laubach, Shaji K Kumar

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Treatment approaches for newly diagnosed myeloma have changed considerably during the past decade, along with a better understanding of the disease heterogeneity. Availability of new drug classes such as proteasome inhibitors and immunomodulatory drugs, and use of these drugs in combinations have led to higher response rates and deeper responses in the vast majority of patients with newly diagnosed myeloma. In addition to improved efficacy, these regimens are tolerated better than those with conventional chemotherapy drugs, which have reduced the early mortality seen in MM, while allowing for successful stem cell collection in patients undergoing stem cell transplant consolidation. Ongoing clinical trials with newer drugs such as monoclonal antibodies are being explored as options for newly diagnosed MM. The optimal regimen continues to evolve and is often dictated by the intent to transplant, age and comorbidities. Despite the increasing response rates seen with the new regimens, autologous stem cell transplantation remains an effective modality for consolidation, further deepening the responses seen with the initial therapy. Post-transplant approaches have further added to the efficacy of this platform with both post-transplant consolidation and maintenance demonstrating value in clinical trials. Currently, the combination of an effective initial therapy followed by one or two autologous stem cell transplants, with or without consolidation followed by maintenance appear to provide the maximum benefit in terms of duration of disease control for patients with newly diagnosed MM.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Pages145-167
Number of pages23
Volume169
DOIs
StatePublished - 2016

Publication series

NameCancer Treatment and Research
Volume169
ISSN (Print)09273042

Fingerprint

Multiple Myeloma
Transplants
Stem Cells
Pharmaceutical Preparations
Maintenance
Clinical Trials
Proteasome Inhibitors
Stem Cell Transplantation
Drug Combinations
Comorbidity
Therapeutics
Monoclonal Antibodies
Drug Therapy
Mortality

Keywords

  • Immunomodulatory drugs
  • Multiple myeloma
  • Proteasome inhibitors
  • Risk stratification
  • Stem cell transplantation

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Laubach, J., & Kumar, S. K. (2016). Management of transplant-eligible patients with newly diagnosed multiple myeloma. In Cancer Treatment and Research (Vol. 169, pp. 145-167). (Cancer Treatment and Research; Vol. 169). Kluwer Academic Publishers. https://doi.org/10.1007/978-3-319-40320-5_9

Management of transplant-eligible patients with newly diagnosed multiple myeloma. / Laubach, Jacob; Kumar, Shaji K.

Cancer Treatment and Research. Vol. 169 Kluwer Academic Publishers, 2016. p. 145-167 (Cancer Treatment and Research; Vol. 169).

Research output: Chapter in Book/Report/Conference proceedingChapter

Laubach, J & Kumar, SK 2016, Management of transplant-eligible patients with newly diagnosed multiple myeloma. in Cancer Treatment and Research. vol. 169, Cancer Treatment and Research, vol. 169, Kluwer Academic Publishers, pp. 145-167. https://doi.org/10.1007/978-3-319-40320-5_9
Laubach J, Kumar SK. Management of transplant-eligible patients with newly diagnosed multiple myeloma. In Cancer Treatment and Research. Vol. 169. Kluwer Academic Publishers. 2016. p. 145-167. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-40320-5_9
Laubach, Jacob ; Kumar, Shaji K. / Management of transplant-eligible patients with newly diagnosed multiple myeloma. Cancer Treatment and Research. Vol. 169 Kluwer Academic Publishers, 2016. pp. 145-167 (Cancer Treatment and Research).
@inbook{f369017810ba4a81b76cbf9dd11d4c55,
title = "Management of transplant-eligible patients with newly diagnosed multiple myeloma",
abstract = "Treatment approaches for newly diagnosed myeloma have changed considerably during the past decade, along with a better understanding of the disease heterogeneity. Availability of new drug classes such as proteasome inhibitors and immunomodulatory drugs, and use of these drugs in combinations have led to higher response rates and deeper responses in the vast majority of patients with newly diagnosed myeloma. In addition to improved efficacy, these regimens are tolerated better than those with conventional chemotherapy drugs, which have reduced the early mortality seen in MM, while allowing for successful stem cell collection in patients undergoing stem cell transplant consolidation. Ongoing clinical trials with newer drugs such as monoclonal antibodies are being explored as options for newly diagnosed MM. The optimal regimen continues to evolve and is often dictated by the intent to transplant, age and comorbidities. Despite the increasing response rates seen with the new regimens, autologous stem cell transplantation remains an effective modality for consolidation, further deepening the responses seen with the initial therapy. Post-transplant approaches have further added to the efficacy of this platform with both post-transplant consolidation and maintenance demonstrating value in clinical trials. Currently, the combination of an effective initial therapy followed by one or two autologous stem cell transplants, with or without consolidation followed by maintenance appear to provide the maximum benefit in terms of duration of disease control for patients with newly diagnosed MM.",
keywords = "Immunomodulatory drugs, Multiple myeloma, Proteasome inhibitors, Risk stratification, Stem cell transplantation",
author = "Jacob Laubach and Kumar, {Shaji K}",
year = "2016",
doi = "10.1007/978-3-319-40320-5_9",
language = "English (US)",
volume = "169",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "145--167",
booktitle = "Cancer Treatment and Research",
address = "Netherlands",

}

TY - CHAP

T1 - Management of transplant-eligible patients with newly diagnosed multiple myeloma

AU - Laubach, Jacob

AU - Kumar, Shaji K

PY - 2016

Y1 - 2016

N2 - Treatment approaches for newly diagnosed myeloma have changed considerably during the past decade, along with a better understanding of the disease heterogeneity. Availability of new drug classes such as proteasome inhibitors and immunomodulatory drugs, and use of these drugs in combinations have led to higher response rates and deeper responses in the vast majority of patients with newly diagnosed myeloma. In addition to improved efficacy, these regimens are tolerated better than those with conventional chemotherapy drugs, which have reduced the early mortality seen in MM, while allowing for successful stem cell collection in patients undergoing stem cell transplant consolidation. Ongoing clinical trials with newer drugs such as monoclonal antibodies are being explored as options for newly diagnosed MM. The optimal regimen continues to evolve and is often dictated by the intent to transplant, age and comorbidities. Despite the increasing response rates seen with the new regimens, autologous stem cell transplantation remains an effective modality for consolidation, further deepening the responses seen with the initial therapy. Post-transplant approaches have further added to the efficacy of this platform with both post-transplant consolidation and maintenance demonstrating value in clinical trials. Currently, the combination of an effective initial therapy followed by one or two autologous stem cell transplants, with or without consolidation followed by maintenance appear to provide the maximum benefit in terms of duration of disease control for patients with newly diagnosed MM.

AB - Treatment approaches for newly diagnosed myeloma have changed considerably during the past decade, along with a better understanding of the disease heterogeneity. Availability of new drug classes such as proteasome inhibitors and immunomodulatory drugs, and use of these drugs in combinations have led to higher response rates and deeper responses in the vast majority of patients with newly diagnosed myeloma. In addition to improved efficacy, these regimens are tolerated better than those with conventional chemotherapy drugs, which have reduced the early mortality seen in MM, while allowing for successful stem cell collection in patients undergoing stem cell transplant consolidation. Ongoing clinical trials with newer drugs such as monoclonal antibodies are being explored as options for newly diagnosed MM. The optimal regimen continues to evolve and is often dictated by the intent to transplant, age and comorbidities. Despite the increasing response rates seen with the new regimens, autologous stem cell transplantation remains an effective modality for consolidation, further deepening the responses seen with the initial therapy. Post-transplant approaches have further added to the efficacy of this platform with both post-transplant consolidation and maintenance demonstrating value in clinical trials. Currently, the combination of an effective initial therapy followed by one or two autologous stem cell transplants, with or without consolidation followed by maintenance appear to provide the maximum benefit in terms of duration of disease control for patients with newly diagnosed MM.

KW - Immunomodulatory drugs

KW - Multiple myeloma

KW - Proteasome inhibitors

KW - Risk stratification

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84989843583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989843583&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-40320-5_9

DO - 10.1007/978-3-319-40320-5_9

M3 - Chapter

VL - 169

T3 - Cancer Treatment and Research

SP - 145

EP - 167

BT - Cancer Treatment and Research

PB - Kluwer Academic Publishers

ER -